---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089340"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:16:55.345273+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sagimet Q2 net loss $8.1M, cash $188.5M; denifanstat fibrosis data positive; Phase 3 plan H2 2024

## Summary
- Cash and marketable securities $188.5M as of June 30, 2024; net loss $8.1M for Q2 2024 vs $6.8M year ago.
- Denifanstat Phase 2b: fibrosis improvement ≥1 stage in 30% vs 14% placebo (ITT); 49% vs 13% in F3 patients.
- Anne Phillips and Jennifer Jarrett appointed to board effective August 1, 2024.
- Phase 3 program for denifanstat in MASH expected to start H2 2024; CRO contract executed.
- R&D expense $6.3M and G&A $4.3M in Q2 2024, up from $4.7M and $2.4M year ago.

## SEC filing metadata
- accession: 0001104659-24-089340
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924089340/0001104659-24-089340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924089340/tm2421625d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089340
- JSON: https://secwatch.observer/filing/0001104659-24-089340.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.